Group for Reproduction in Animals, Vaccinology and Infectious Diseases (GRAVID™), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-2771, United States; Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, United States; Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-2771, United States.
Group for Reproduction in Animals, Vaccinology and Infectious Diseases (GRAVID™), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-2771, United States; Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, United States.
Vet Immunol Immunopathol. 2021 Jul;237:110254. doi: 10.1016/j.vetimm.2021.110254. Epub 2021 May 24.
This study was performed to elucidate whether the route of booster vaccination affects the immune response against respiratory vaccine viruses in pre-weaning beef calves that receive primary intranasal (IN) vaccination during the first month of life. The objective was to compare the serum neutralizing antibody (SNA) titers to BHV1, BRSV, and BPI3V, cytokine mRNA expression and mucosal BHV1- and BRSV-specific IgA in nasal secretions following administration of IN or subcutaneous (SC) modified-live virus (MLV) booster vaccines 60 days after primary IN vaccination in young beef calves. Twenty-one beef calves were administered 2 mL of an IN MLV vaccine containing BHV1, BRSV, and BPI3V (Inforce3®) between one and five weeks of age. Sixty days after primary vaccination, calves were randomly assigned to one of two groups: IN-MLV (n = 11): Calves received 2 mL of the same IN MLV vaccine used for primary vaccination and 2 mL of a SC MLV vaccine containing BVDV1 & 2 (Bovi- Shield GOLD® BVD). SC-MLV (n = 10): Calves were administered 2 mL of a MLV vaccine containing, BHV1, BRSV, BPI3V, and BVDV1 & 2 (Bovi-Shield GOLD® 5). Blood and nasal secretion samples were collected on days -61 (primary vaccination), -28, -14, 0 (booster vaccination), 14, 21, 28, 42 and 60 for determination of SNA titers, cytokine gene expression analysis and nasal virus-specific IgA concentrations. Statistical analysis was performed using a repeated measures analysis through PROC GLIMMIX of SAS®. Booster vaccination by neither IN nor SC routes induced a significant increase in SNA titers against BHV1, BRSV, and BPI3V. Subcutaneous booster vaccination induced significantly greater BRSV-specific SNA titers (on day 42) and IgA concentration in nasal secretions (on days 21 and 42) compared to calves receiving IN booster vaccination. Both IN and SC booster vaccination were able to stimulate the production of BHV1-specific IgA in nasal secretions. In summary, booster vaccination of young beef calves using either SC or IN route two months after IN MLV primary vaccination resulted in comparable SNA titers, cytokine gene expression profile and virus-specific IgA concentration in nasal secretions. Only a few differences in the systemic and mucosal immune response against BHV1 and BRSV were observed. Subcutaneous booster vaccination induced significantly greater BRSV-specific SNA and secretory IgA titers compared to IN booster vaccination.
本研究旨在阐明在生命的第一个月接受鼻内(IN)初免接种的犊牛中,加强免疫接种的途径是否会影响呼吸道疫苗病毒的免疫反应。目的是比较经 IN 或皮下(SC)途径接种改良活病毒(MLV)加强疫苗 60 天后,犊牛血清中和抗体(SNA)滴度、鼻分泌物中细胞因子 mRNA 表达和针对 BHV1 和 BRSV 的黏膜特异性 IgA,以评估其对犊牛的影响。21 头犊牛在 1 至 5 周龄时接受 2 mL 含有 BHV1、BRSV 和 BPI3V 的 IN MLV 疫苗(Inforce3®)。初免接种 60 天后,将犊牛随机分为两组:IN-MLV(n=11):犊牛接受 2 mL 与初免接种相同的 IN MLV 疫苗,以及 2 mL 含有 BVDV1 和 2 的 SC MLV 疫苗(Bovi-Shield GOLD® BVD)。SC-MLV(n=10):犊牛接受 2 mL 含有 BHV1、BRSV、BPI3V 和 BVDV1 和 2 的 MLV 疫苗(Bovi-Shield GOLD® 5)。在第-61 天(初免接种)、-28 天、-14 天、0 天(加强接种)、14 天、21 天、28 天、42 天和 60 天采集血液和鼻分泌物样本,以确定 SNA 滴度、细胞因子基因表达分析和鼻病毒特异性 IgA 浓度。使用 SAS®中的 PROC GLIMMIX 通过重复测量分析进行统计分析。IN 和 SC 途径的加强免疫接种均未显著提高犊牛对 BHV1、BRSV 和 BPI3V 的 SNA 滴度。与接受 IN 加强免疫接种的犊牛相比,SC 加强免疫接种可显著提高 BRSV 特异性 SNA 滴度(第 42 天)和鼻分泌物中的 IgA 浓度(第 21 天和第 42 天)。IN 和 SC 加强免疫接种均能刺激鼻分泌物中产生 BHV1 特异性 IgA。总之,在 IN MLV 初免接种两个月后,无论是通过 IN 还是 SC 途径对犊牛进行加强免疫接种,均可在鼻分泌物中产生相似的 SNA 滴度、细胞因子基因表达谱和病毒特异性 IgA 浓度。仅观察到针对 BHV1 和 BRSV 的系统和黏膜免疫反应的一些差异。与 IN 加强免疫接种相比,SC 加强免疫接种可显著提高 BRSV 特异性 SNA 和分泌型 IgA 滴度。